Bioventus BVS
- Market cap
- $1.1B
- PE
- 17.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.9×
- EV/EBIT
- 23.6×
- Revenue, 12 months
- $585.6M
- +4% on a year ago
- Net margin
- 9.4%
- Free cash flow yield
- 8.5%
Bioventus trades at 17.1× trailing earnings. Revenue was $585.6M over the last twelve months, up 4% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $135.4M+8% | $129.5M+9% | $151.2M+10% | $139M+15% | $153.6M+14% | $123.9M−4% | $147.7M−2% | $138.7M−0% | $157.9M+3% | $132.1M+7% | $153.2M+4% | $142.4M+3% | |
| Cost of revenue | $49.1M−5% | $41.1M−9% | $47.6M−1% | $45.4M+8% | $51M+4% | $40.8M−1% | $45.6M−4% | $44.4M−2% | $49.1M−4% | $41.3M+1% | $47.5M+4% | $45.3M+2% |
| Gross profit | $86.3M+16% | $88.4M+20% | $103.6M+16% | $93.6M+19% | $102.7M+19% | $83.1M−6% | $102.1M−2% | $94.2M+1% | $108.8M+6% | $90.8M+9% | $105.7M+4% | $97.1M+3% |
| R&D | $3.3M−45% | $2.6M−30% | $4.2M+24% | $3.8M+28% | $3.3M+0% | $3M+15% | $3.2M−25% | $2.9M−24% | $3M−8% | $2.5M−18% | $3.2M+0% | $3.4M+18% |
| SG&A | $78.4M+1% | $78.8M−3% | $96.7M+29% | $81.5M+17% | $86.9M+11% | $73.5M−7% | $79.1M−18% | $78.7M−4% | $82.8M−5% | $78.3M+7% | $82.7M+5% | $82.9M+6% |
| $1.2M | $4.9M | −$31.5M | $3.6M+51% | $7.7M+561% | $4.9M−1% | $18.4M | $11.3M+209% | $19.5M+153% | $8.4M+73% | $19.1M+4% | $9.7M−14% | |
| Interest expense | $10.3M+39% | $10.3M+7% | $9.9M−6% | $9.5M−6% | $9M−13% | $7.5M−27% | $7.5M−25% | $6.2M−35% | $5.3M−41% | $4.3M−42% | $4.1M−46% | $3.8M−39% |
| Pre-tax income | −$8.4M−74% | −$5.5M−95% | −$41.6M+855% | −$5.3M−36% | −$53K−99% | −$3.4M−38% | $10.3M | $4.7M | $14.1M | $4.5M | $15.3M+48% | $6.2M+32% |
| −$750K−93% | $907K | −$7.3M | $589K−2% | $550K | −$95K | $1M | $664K+13% | −$3.2M | $571K | −$20.9M | −$701K | |
| Net income | −$6.1M−81% | −$4.9M−97% | −$25.7M+598% | −$5.2M−29% | −$388K−94% | −$2.6M−46% | $7.5M | $3.2M | $14.8M | $3.1M | $33.4M+348% | $6M+90% |
| −$0.10−81% | −$0.08−96% | −$0.40+567% | −$0.08−33% | −$0.01−90% | −$0.04−50% | $0.11 | $0.05 | $0.21 | $0.04 | $0.47+327% | $0.08+60% | |
| 63.1M+2% | 63.4M+2% | 64.1M+2% | 65.3M+4% | 65.5M+4% | 66M+4% | 68.5M+7% | 68.8M+6% | 69.3M+6% | 70M+6% | 70.8M+3% | 72.5M+5% |
Interest expense: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| UFPTUFP Technologies | $2.2B | 30.6× | 25.6× | 3.5× | +7% | 11.4% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| Peer median | $1.3B | 29.6× | 44.1× | 2.1× | +9% | 6.5% |
More on Bioventus
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 46Medical instruments and supplies stocks with the highest free cash flow yield
- #8of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .